Journal of Hematology & Thromboembolic Diseases
Open Access

Anticoagulant treatment - a single centre study

Webinar on 2^nd European Congress on Hematology

January 24-25, 2022 | Webinar

Lucia Stanciakova, Miroslava Dobrotova, Pavol Holly, Peter Kubisz, Jan Stasko

National Centre of Haemostasis and Thrombosis, Department of Haematology and Transfusion Medicine, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, Slovakia

Scientific Tracks Abstracts: J Hematol Thrombo Dis

Abstract :

Abstract:
The authors present the population of patients with venous thromboembolism, treated with anticoagulants according to the age, sex, family history and results of thrombophilic screening. Simultaneously, they compare the possibilites of detection of the effectiveness of anticoagulant treatment and assess the markers indicating the activation of haemostasis. The dose of anticoagulation treatment was individually modified in the patients based on the results of the special tests of haemostasis, such as coagulation factor FVIII activity, protein S function, level of D-dimers, anti-Xa/anti-IIa activity according to the type of anticoagulant used in the particular patient and his/her clinical state. Anticoagulant treatment in observed patients was tolerated well, without any significant bleeding complications. The authors summed-up also the resence of other side events. This study complies with the Declaration of Helsinki and informed consent of the patient included in the study was obtained.

Biography :

Lucia Stanciakova, MD, PhD. was awarded the degree Doctor of Medicine in 2013 and completed her postgraduate study in 2017. Now she works as a haematologist and assistant lecturer at the National Centre of Haemostasis and Thrombosis, Department of Haematology and Transfusion Medicine, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Slovakia. Her research interest includes thrombophilic states and their genetics, haemostasis in vascular disorders and oncological diseases, high-risk pregnancy, monitoring of the effectiveness of direct oral anticoagulants and antiplatelet treatment.